142 related articles for article (PubMed ID: 16263590)
1. Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.
Mazzotta S; Gozzetti A; Pirrotta MT; Bocchia M; Sammassimo S; Bucalossi A; Lauria F
Leuk Lymphoma; 2005 Dec; 46(12):1837-8. PubMed ID: 16263590
[TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
Castro TB; Hallack Neto AE; Atalla A; Ribeiro LC
Braz J Med Biol Res; 2016; 49(6):e5128. PubMed ID: 27254660
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide-induced severe neutropenia during treatment of multiple myeloma.
Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y
Int J Hematol; 2004 Apr; 79(3):283-8. PubMed ID: 15168599
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide as initial therapy for early-stage myeloma.
Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE
Leukemia; 2003 Apr; 17(4):775-9. PubMed ID: 12682636
[TBL] [Abstract][Full Text] [Related]
5. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature.
Prasad HK; Kaushal V; Mehta P
Am J Hematol; 2007 Sep; 82(9):855-7. PubMed ID: 17570510
[TBL] [Abstract][Full Text] [Related]
6. Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.
Magalini F; Stella A; Sansoni P
Intern Emerg Med; 2008 Dec; 3(4):383-5. PubMed ID: 18320148
[No Abstract] [Full Text] [Related]
7. [Thalidomide induced peripheral neuropathy in multiple myeloma patients].
Banach M; Jurczyszyn A; Skotnicki A
Przegl Lek; 2015; 72(11):629-35. PubMed ID: 27012121
[TBL] [Abstract][Full Text] [Related]
8. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
[TBL] [Abstract][Full Text] [Related]
10. [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma].
Ikebe T; Ogata M; Miyazaki M; Miyazaki Y; Ohtsuka E; Saburi Y; Goto K; Ikewaki J; Kohno K; Uno N; Imamura T; Akagi T; Kadota J
Rinsho Ketsueki; 2010 Feb; 51(2):114-21. PubMed ID: 20379102
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide in patients with advanced multiple myeloma.
Yakoub-Agha I; Moreau P; Leyvraz S; Berthou C; Payen C; Dumontet C; Grosbois B; Beris P; Duguet C; Attal M; Harousseau JL; Facon T;
Hematol J; 2000; 1(3):186-9. PubMed ID: 11920188
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level].
Ma XR; Chen YX; Liu J; Zhang WG; Cao XM; He AL; Yang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1312-5. PubMed ID: 19099634
[TBL] [Abstract][Full Text] [Related]
13. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.
Dimopoulos MA; Hamilos G; Zomas A; Gika D; Efstathiou E; Grigoraki V; Poziopoulos C; Xilouri I; Zorzou MP; Anagnostopoulos N; Anagnostopoulos A
Hematol J; 2004; 5(2):112-7. PubMed ID: 15048060
[TBL] [Abstract][Full Text] [Related]
14. Management of treatment-related adverse events in patients with multiple myeloma.
Mateos MV
Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
[TBL] [Abstract][Full Text] [Related]
15. Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.
Yakoub-Agha I; Mary JY; Hulin C; Doyen C; Marit G; Benboubker L; Voillat L; Moreau P; Berthou C; Stoppa AM; Maloisel F; Rodon P; Dib M; Pegourie B; Casassus P; Slama B; Damaj G; Zerbib R; Harousseau JL; Mohty M; Facon T;
Eur J Haematol; 2012 Mar; 88(3):249-59. PubMed ID: 22023551
[TBL] [Abstract][Full Text] [Related]
16. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
17. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
18. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Ciepłuch H; Baran W; Hellmann A
Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis.
Hayashi T; Yamaguchi I; Saitoh H; Takagi M; Nonaka Y; Nomura T
Intern Med; 2003 Jul; 42(7):605-8. PubMed ID: 12879955
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
